Fig. 3: Kaplan–Meier estimates of PFS for patients with expanded high- or standard-risk cytogenetic abnormalities receiving ixazomib- vs placebo-based therapy. | Blood Cancer Journal

Fig. 3: Kaplan–Meier estimates of PFS for patients with expanded high- or standard-risk cytogenetic abnormalities receiving ixazomib- vs placebo-based therapy.

From: A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

Fig. 3: Kaplan–Meier estimates of PFS for patients with expanded high- or standard-risk cytogenetic abnormalities receiving ixazomib- vs placebo-based therapy.The alternative text for this image may have been generated using AI.

A Expanded high-risk cytogenetic abnormalities, and B standard-risk (complement of expanded high-risk) abnormalities. CI confidence interval, HR hazard ratio, PFS progression-free survival.

Back to article page